Pharmacosmos initiates PhII trial with acquired drug candidate
Pharmacosmos has enrolled the first patient in a Phase II trial with SP-420, which the company acquired with acquisition of American Abfero Pharmaceuticals in 2021.
Family-owned iron therapy company Pharmacosmos is one step closer to the market with a drug for treating transfusional iron overload (TIO) in people with transfusion-dependent β-thalassemia.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
